


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
CI
Cigna
$277.28
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
Chart
$244.41 (+13.45%)
$304.03 (-8.80%)
$309.78 (-10.49%)
$294.03 (-5.70%)
CI has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

CI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
CI Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CI Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is CI current stock price?
What are CI stock strengths?
What is CI Risk Level?
What is CI market cap and volume?
What is CI current Stock IQ?
Should I buy CI stock right now?
Is CI a Strong Buy right now?
What does a 'Strong Buy' rating mean for CI?
What does a 'Strong Sell' rating mean for CI?
What factors influence CI's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
CI
Cigna
Current Price
$277.28
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market

Chart
$244.41 (+13.45%)
$304.03 (-8.80%)
$309.78 (-10.49%)
$294.03 (-5.70%)
CI Analysts Opinion
CI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
CI Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CI Street Sentiment is extremely bullish and have positive views on the near-term outlook
CI has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
CI Latest Analysis
Bank of America Securities Maintains a Buy on The Cigna Group (CI) Sets a $378 PT. The Cigna Group (NYSE:CI) is one of the best low volatility large cap stocks to invest in. Bank of America Securities analyst Kevin Fischbeck maintained a Buy rating on The Cigna Group (NYSE:CI) on November 21 setting a price target of $378. The analyst based the rating on the companys overall financial outlook and strategic [….]
Today
Cigna: Now Is A Prime Buying Opportunity.
Mon Nov 24, 2025
Heres Why The Cigna Group (CI) Traded Lower in Q3.
Thu Nov 20, 2025
ABEO: First Patient Treated with Zevaskyn® Pushed to 4Q25 Following Assay Optimization. By Business UpdateFirst Patient Treated with Zevaskyn® Pushed to 4Q25The first patient treated with Zevaskyn was pushed back to the fourth quarter of 2025 following the optimization of a release assay during the third quarter of 2025. A full batch of drug product was produced following biopsy collection from a patient in August 2025 however that the product could not be released because a rapid sterility assa
Fri Nov 14, 2025
The Cigna Group (CI) Presents at UBS Global Healthcare Conference 2025 Transcript.
Wed Nov 12, 2025
The Cigna Group Named Top Dividend Stock With Insider Buying and 2.28% Yield (CI). In this series we look through the most recent Dividend Channel DividendRank report and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insiders view of
Mon Nov 10, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.